1
|
Schumski A, Ortega-Gómez A, Wichapong K, Winter C, Lemnitzer P, Viola JR, Pinilla-Vera M, Folco E, Solis-Mezarino V, Völker-Albert M, Maas SL, Pan C, Perez Olivares L, Winter J, Hackeng T, Karlsson MCI, Zeller T, Imhof A, Baron RM, Nicolaes GAF, Libby P, Maegdefessel L, Kamp F, Benoit M, Döring Y, Soehnlein O. Endotoxinemia Accelerates Atherosclerosis Through Electrostatic Charge-Mediated Monocyte Adhesion. Circulation 2020; 143:254-266. [PMID: 33167684 DOI: 10.1161/circulationaha.120.046677] [Citation(s) in RCA: 92] [Impact Index Per Article: 23.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
BACKGROUND Acute infection is a well-established risk factor of cardiovascular inflammation increasing the risk for a cardiovascular complication within the first weeks after infection. However, the nature of the processes underlying such aggravation remains unclear. Lipopolysaccharide derived from Gram-negative bacteria is a potent activator of circulating immune cells including neutrophils, which foster inflammation through discharge of neutrophil extracellular traps (NETs). Here, we use a model of endotoxinemia to link acute infection and subsequent neutrophil activation with acceleration of vascular inflammation Methods: Acute infection was mimicked by injection of a single dose of lipopolysaccharide into hypercholesterolemic mice. Atherosclerosis burden was studied by histomorphometric analysis of the aortic root. Arterial myeloid cell adhesion was quantified by intravital microscopy. RESULTS Lipopolysaccharide treatment rapidly enhanced atherosclerotic lesion size by expansion of the lesional myeloid cell accumulation. Lipopolysaccharide treatment led to the deposition of NETs along the arterial lumen, and inhibition of NET release annulled lesion expansion during endotoxinemia, thus suggesting that NETs regulate myeloid cell recruitment. To study the mechanism of monocyte adhesion to NETs, we used in vitro adhesion assays and biophysical approaches. In these experiments, NET-resident histone H2a attracted monocytes in a receptor-independent, surface charge-dependent fashion. Therapeutic neutralization of histone H2a by antibodies or by in silico designed cyclic peptides enables us to reduce luminal monocyte adhesion and lesion expansion during endotoxinemia. CONCLUSIONS Our study shows that NET-associated histone H2a mediates charge-dependent monocyte adhesion to NETs and accelerates atherosclerosis during endotoxinemia.
Collapse
Affiliation(s)
- Ariane Schumski
- Institute for Cardiovascular Prevention (IPEK), LMU Munich Hospital, Germany (A.S., A.O.-G., C.W., P. Lemnitzer, J.R.V., C.P., L.P.O., J.W., Y.D., O.S.)
- German Center for Cardiovascular Research (DZHK), partner site Munich Heart Alliance (MHA), Munich, Germany (A.S., A.O.-G., S.L.M., L.M., O.S.)
| | - Almudena Ortega-Gómez
- Institute for Cardiovascular Prevention (IPEK), LMU Munich Hospital, Germany (A.S., A.O.-G., C.W., P. Lemnitzer, J.R.V., C.P., L.P.O., J.W., Y.D., O.S.)
- German Center for Cardiovascular Research (DZHK), partner site Munich Heart Alliance (MHA), Munich, Germany (A.S., A.O.-G., S.L.M., L.M., O.S.)
| | - Kanin Wichapong
- Department of Biochemistry, CARIM, University Maastricht, The Netherlands (K.W., T.H., G.A.F.N.)
| | - Carla Winter
- Institute for Cardiovascular Prevention (IPEK), LMU Munich Hospital, Germany (A.S., A.O.-G., C.W., P. Lemnitzer, J.R.V., C.P., L.P.O., J.W., Y.D., O.S.)
| | - Patricia Lemnitzer
- Institute for Cardiovascular Prevention (IPEK), LMU Munich Hospital, Germany (A.S., A.O.-G., C.W., P. Lemnitzer, J.R.V., C.P., L.P.O., J.W., Y.D., O.S.)
| | - Joana R Viola
- Institute for Cardiovascular Prevention (IPEK), LMU Munich Hospital, Germany (A.S., A.O.-G., C.W., P. Lemnitzer, J.R.V., C.P., L.P.O., J.W., Y.D., O.S.)
| | - Mayra Pinilla-Vera
- Division of Pulmonary and Critical Care Medicine (M.P.-V., R.M.B.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA
| | - Eduardo Folco
- Division of Cardiovascular Medicine (E.F., P. L.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA
| | | | | | - Sanne L Maas
- German Center for Cardiovascular Research (DZHK), partner site Munich Heart Alliance (MHA), Munich, Germany (A.S., A.O.-G., S.L.M., L.M., O.S.)
| | - Chang Pan
- Institute for Cardiovascular Prevention (IPEK), LMU Munich Hospital, Germany (A.S., A.O.-G., C.W., P. Lemnitzer, J.R.V., C.P., L.P.O., J.W., Y.D., O.S.)
| | - Laura Perez Olivares
- Institute for Cardiovascular Prevention (IPEK), LMU Munich Hospital, Germany (A.S., A.O.-G., C.W., P. Lemnitzer, J.R.V., C.P., L.P.O., J.W., Y.D., O.S.)
| | - Janine Winter
- Institute for Cardiovascular Prevention (IPEK), LMU Munich Hospital, Germany (A.S., A.O.-G., C.W., P. Lemnitzer, J.R.V., C.P., L.P.O., J.W., Y.D., O.S.)
| | - Tilman Hackeng
- Department of Biochemistry, CARIM, University Maastricht, The Netherlands (K.W., T.H., G.A.F.N.)
| | - Mikael C I Karlsson
- Department of Microbiology, Tumor and Cell Biology (M.C.I.K.), Karolinska Institute, Stockholm, Sweden
| | - Tanja Zeller
- Department of General and Interventional Cardiology, University Heart Center Hamburg, Germany (T.Z.)
- German Center for Cardiovascular Research (DZHK), Partner Site Hamburg, Lübeck, Kiel Hamburg, Germany (T.Z.)
| | - Axel Imhof
- BMC, Chromatin Proteomics Group, Department of Molecular Biology (A.I.), LMU München, Germany
| | - Rebecca M Baron
- Division of Pulmonary and Critical Care Medicine (M.P.-V., R.M.B.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA
| | - Gerry A F Nicolaes
- Department of Biochemistry, CARIM, University Maastricht, The Netherlands (K.W., T.H., G.A.F.N.)
| | - Peter Libby
- Division of Cardiovascular Medicine (E.F., P. L.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA
| | - Lars Maegdefessel
- German Center for Cardiovascular Research (DZHK), partner site Munich Heart Alliance (MHA), Munich, Germany (A.S., A.O.-G., S.L.M., L.M., O.S.)
- Department of Vascular and Endovascular Surgery, Technical University Munich, Germany (L.M.)
| | - Frits Kamp
- BMC, Metabolic Biochemistry (F.K.), LMU München, Germany
| | - Martin Benoit
- Center for Nano Science (CeNS), Department of Physics, Munich, Germany (M.B.)
| | - Yvonne Döring
- Institute for Cardiovascular Prevention (IPEK), LMU Munich Hospital, Germany (A.S., A.O.-G., C.W., P. Lemnitzer, J.R.V., C.P., L.P.O., J.W., Y.D., O.S.)
- Division of Angiology, Swiss Cardiovascular Centre, Inselspital, Bern University Hospital, University of Bern, Switzerland (Y.D.)
| | - Oliver Soehnlein
- Institute for Cardiovascular Prevention (IPEK), LMU Munich Hospital, Germany (A.S., A.O.-G., C.W., P. Lemnitzer, J.R.V., C.P., L.P.O., J.W., Y.D., O.S.)
- German Center for Cardiovascular Research (DZHK), partner site Munich Heart Alliance (MHA), Munich, Germany (A.S., A.O.-G., S.L.M., L.M., O.S.)
- Department of Physiology and Pharmacology (FyFa) (O.S.), Karolinska Institute, Stockholm, Sweden
| |
Collapse
|
2
|
Ferraro B, Leoni G, Hinkel R, Ormanns S, Paulin N, Ortega-Gomez A, Viola JR, de Jong R, Bongiovanni D, Bozoglu T, Maas SL, D'Amico M, Kessler T, Zeller T, Hristov M, Reutelingsperger C, Sager HB, Döring Y, Nahrendorf M, Kupatt C, Soehnlein O. Pro-Angiogenic Macrophage Phenotype to Promote Myocardial Repair. J Am Coll Cardiol 2020; 73:2990-3002. [PMID: 31196457 DOI: 10.1016/j.jacc.2019.03.503] [Citation(s) in RCA: 102] [Impact Index Per Article: 25.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/04/2018] [Revised: 03/12/2019] [Accepted: 03/19/2019] [Indexed: 11/25/2022]
Abstract
BACKGROUND Heart failure following myocardial infarction (MI) remains one of the major causes of death worldwide, and its treatment is a crucial challenge of cardiovascular medicine. An attractive therapeutic strategy is to stimulate endogenous mechanisms of myocardial regeneration. OBJECTIVES This study evaluates the potential therapeutic treatment with annexin A1 (AnxA1) to induce cardiac repair after MI. METHODS AnxA1 knockout (AnxA1-/-) and wild-type mice underwent MI induced by ligation of the left anterior descending coronary artery. Cardiac functionality was assessed by longitudinal echocardiographic measurements. Histological, fluorescence-activated cell sorting, dot blot analysis, and in vitro/ex vivo studies were used to assess the myocardial neovascularization, macrophage content, and activity in response to AnxA1. RESULTS AnxA1-/- mice showed a reduced cardiac functionality and an expansion of proinflammatory macrophages in the ischemic area. Cardiac macrophages from AnxA1-/- mice exhibited a dramatically reduced ability to release the proangiogenic mediator vascular endothelial growth factor (VEGF)-A. However, AnxA1 treatment enhanced VEGF-A release from cardiac macrophages, and its delivery in vivo markedly improved cardiac performance. The positive effect of AnxA1 treatment on cardiac performance was abolished in wild-type mice transplanted with bone marrow derived from Cx3cr1creERT2Vegfflox/flox or in mice depleted of macrophages. Similarly, cardioprotective effects of AnxA1 were obtained in pigs in which full-length AnxA1 was overexpressed by use of a cardiotropic adeno-associated virus. CONCLUSIONS AnxA1 has a direct action on cardiac macrophage polarization toward a pro-angiogenic, reparative phenotype. AnxA1 stimulated cardiac macrophages to release high amounts of VEGF-A, thus inducing neovascularization and cardiac repair.
Collapse
Affiliation(s)
- Bartolo Ferraro
- Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-Universität Munich, Munich, Germany; Deutsches Zentrum für Herz-Kreislaufforschung (DZHK), partner site Munich Heart Alliance, Munich, Germany
| | - Giovanna Leoni
- Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-Universität Munich, Munich, Germany; Deutsches Zentrum für Herz-Kreislaufforschung (DZHK), partner site Munich Heart Alliance, Munich, Germany
| | - Rabea Hinkel
- Deutsches Zentrum für Herz-Kreislaufforschung (DZHK), partner site Munich Heart Alliance, Munich, Germany; Medizinische Klinik I, TU Munich, Germany; Deutsches Primatenzentrum GmbH, Leibniz-Institut für Primatenforschung, Department of Laboratory Animal Science, Göttingen, Germany
| | - Steffen Ormanns
- Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany
| | - Nicole Paulin
- Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-Universität Munich, Munich, Germany; Deutsches Zentrum für Herz-Kreislaufforschung (DZHK), partner site Munich Heart Alliance, Munich, Germany
| | - Almudena Ortega-Gomez
- Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-Universität Munich, Munich, Germany; Deutsches Zentrum für Herz-Kreislaufforschung (DZHK), partner site Munich Heart Alliance, Munich, Germany
| | - Joana R Viola
- Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-Universität Munich, Munich, Germany; Deutsches Zentrum für Herz-Kreislaufforschung (DZHK), partner site Munich Heart Alliance, Munich, Germany
| | - Renske de Jong
- Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-Universität Munich, Munich, Germany
| | - Dario Bongiovanni
- Deutsches Zentrum für Herz-Kreislaufforschung (DZHK), partner site Munich Heart Alliance, Munich, Germany; Medizinische Klinik I, TU Munich, Germany
| | | | - Sanne L Maas
- Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-Universität Munich, Munich, Germany; Deutsches Zentrum für Herz-Kreislaufforschung (DZHK), partner site Munich Heart Alliance, Munich, Germany
| | - Michele D'Amico
- Department of Experimental Medicine, University of Campania, Campania, Italy
| | - Thorsten Kessler
- Deutsches Zentrum für Herz-Kreislaufforschung (DZHK), partner site Munich Heart Alliance, Munich, Germany; Department of Cardiology, German Heart Center Munich, Munich, Germany
| | - Tanja Zeller
- DZHK, Partner Site Hamburg/Kiel/Lübeck, Hamburg, Germany; Clinic for Cardiology, University Heart Center, Hamburg, Germany
| | - Michael Hristov
- Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-Universität Munich, Munich, Germany
| | - Chris Reutelingsperger
- Department of Biochemistry, Cardiovascular Research Institute Maastricht, University Maastricht, Maastricht, the Netherlands
| | - Hendrik B Sager
- Deutsches Zentrum für Herz-Kreislaufforschung (DZHK), partner site Munich Heart Alliance, Munich, Germany; Department of Cardiology, German Heart Center Munich, Munich, Germany
| | - Yvonne Döring
- Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-Universität Munich, Munich, Germany; Deutsches Zentrum für Herz-Kreislaufforschung (DZHK), partner site Munich Heart Alliance, Munich, Germany
| | - Matthias Nahrendorf
- Center for Systems Biology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
| | - Christian Kupatt
- Deutsches Zentrum für Herz-Kreislaufforschung (DZHK), partner site Munich Heart Alliance, Munich, Germany; Medizinische Klinik I, TU Munich, Germany
| | - Oliver Soehnlein
- Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-Universität Munich, Munich, Germany; Deutsches Zentrum für Herz-Kreislaufforschung (DZHK), partner site Munich Heart Alliance, Munich, Germany; Department of Physiology and Pharmacology (FyFa) and Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
| |
Collapse
|
3
|
Paulin N, Viola JR, Maas SL, de Jong R, Fernandes-Alnemri T, Weber C, Drechsler M, Döring Y, Soehnlein O. Double-Strand DNA Sensing Aim2 Inflammasome Regulates Atherosclerotic Plaque Vulnerability. Circulation 2019; 138:321-323. [PMID: 30012706 DOI: 10.1161/circulationaha.117.033098] [Citation(s) in RCA: 56] [Impact Index Per Article: 11.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- Nicole Paulin
- Institute for Cardiovascular Prevention (IPEK), LMU Munich, Germany (N.P., J.R.V., S.L.M., R.d.J., C.W., M.D., Y.D., O.S.).,DZHK, partner site Munich Heart Alliance, Germany (N.P., J.R.V., C.W., M.D., Y.D., O.S.).,Centre for Preclinical Research, Klinikum Rechts der Isar, Munich, Germany (N.P.)
| | - Joana R Viola
- Institute for Cardiovascular Prevention (IPEK), LMU Munich, Germany (N.P., J.R.V., S.L.M., R.d.J., C.W., M.D., Y.D., O.S.).,DZHK, partner site Munich Heart Alliance, Germany (N.P., J.R.V., C.W., M.D., Y.D., O.S.)
| | - Sanne L Maas
- Institute for Cardiovascular Prevention (IPEK), LMU Munich, Germany (N.P., J.R.V., S.L.M., R.d.J., C.W., M.D., Y.D., O.S.)
| | - Renske de Jong
- Institute for Cardiovascular Prevention (IPEK), LMU Munich, Germany (N.P., J.R.V., S.L.M., R.d.J., C.W., M.D., Y.D., O.S.)
| | - Teresa Fernandes-Alnemri
- Department of Biochemistry and Molecular Biology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA (T.F.-A.)
| | - Christian Weber
- Institute for Cardiovascular Prevention (IPEK), LMU Munich, Germany (N.P., J.R.V., S.L.M., R.d.J., C.W., M.D., Y.D., O.S.).,DZHK, partner site Munich Heart Alliance, Germany (N.P., J.R.V., C.W., M.D., Y.D., O.S.)
| | - Maik Drechsler
- Institute for Cardiovascular Prevention (IPEK), LMU Munich, Germany (N.P., J.R.V., S.L.M., R.d.J., C.W., M.D., Y.D., O.S.).,DZHK, partner site Munich Heart Alliance, Germany (N.P., J.R.V., C.W., M.D., Y.D., O.S.)
| | - Yvonne Döring
- Institute for Cardiovascular Prevention (IPEK), LMU Munich, Germany (N.P., J.R.V., S.L.M., R.d.J., C.W., M.D., Y.D., O.S.).,DZHK, partner site Munich Heart Alliance, Germany (N.P., J.R.V., C.W., M.D., Y.D., O.S.)
| | - Oliver Soehnlein
- Institute for Cardiovascular Prevention (IPEK), LMU Munich, Germany (N.P., J.R.V., S.L.M., R.d.J., C.W., M.D., Y.D., O.S.). .,DZHK, partner site Munich Heart Alliance, Germany (N.P., J.R.V., C.W., M.D., Y.D., O.S.).,Department of Physiology and Pharmacology (FyFa), Karolinska Institutet, Stockholm, Sweden (O.S.)
| |
Collapse
|
4
|
Maas SL, Soehnlein O, Viola JR. Organ-Specific Mechanisms of Transendothelial Neutrophil Migration in the Lung, Liver, Kidney, and Aorta. Front Immunol 2018; 9:2739. [PMID: 30538702 PMCID: PMC6277681 DOI: 10.3389/fimmu.2018.02739] [Citation(s) in RCA: 82] [Impact Index Per Article: 13.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2018] [Accepted: 11/07/2018] [Indexed: 12/13/2022] Open
Abstract
Immune responses are dependent on the recruitment of leukocytes to the site of inflammation. The classical leukocyte recruitment cascade, consisting of capture, rolling, arrest, adhesion, crawling, and transendothelial migration, is thoroughly studied but mostly in model systems, such as the cremasteric microcirculation. This cascade paradigm, which is widely accepted, might be applicable to many tissues, however recruitment mechanisms might substantially vary in different organs. Over the last decade, several studies shed light on organ-specific mechanisms of leukocyte recruitment. An improved awareness of this matter opens new therapeutic windows and allows targeting inflammation in a tissue-specific manner. The aim of this review is to summarize the current understanding of the leukocyte recruitment in general and how this varies in different organs. In particular we focus on neutrophils, as these are the first circulating leukocytes to reach the site of inflammation. Specifically, the recruitment mechanism in large arteries, as well as vessels in the lungs, liver, and kidney will be addressed.
Collapse
Affiliation(s)
- Sanne L Maas
- Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-Universität München, Munich, Germany.,German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany
| | - Oliver Soehnlein
- Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-Universität München, Munich, Germany.,German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany.,Department of Physiology and Pharmacology (FyFa) and Department of Medicine, Karolinska Institutet, Stockholm, Sweden
| | - Joana R Viola
- Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-Universität München, Munich, Germany.,German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany
| |
Collapse
|
5
|
Viola JR, Lemnitzer P, Paulin N, Drechsler M, Nazari-Jahantigh M, Maas S, De Jong RJ, Winter J, Schober A, Weber C, Atabai K, Soehnlein O. Deletion of MFGE8 Inhibits Neointima Formation upon Arterial Damage. Thromb Haemost 2018; 118:1340-1342. [PMID: 29864782 DOI: 10.1055/s-0038-1649522] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
Affiliation(s)
- Joana R Viola
- Institute for Cardiovascular Prevention, LMU Munich, Munich, Germany.,Department of Pathology, Academic Medical Center, Amsterdam University, The Netherlands.,DZHK, Partner Site Munich Heart Alliance, Munich, Germany
| | | | - Nicole Paulin
- Institute for Cardiovascular Prevention, LMU Munich, Munich, Germany
| | - Maik Drechsler
- Institute for Cardiovascular Prevention, LMU Munich, Munich, Germany.,Department of Pathology, Academic Medical Center, Amsterdam University, The Netherlands.,DZHK, Partner Site Munich Heart Alliance, Munich, Germany
| | - Maliheh Nazari-Jahantigh
- Institute for Cardiovascular Prevention, LMU Munich, Munich, Germany.,DZHK, Partner Site Munich Heart Alliance, Munich, Germany
| | - Sanne Maas
- Institute for Cardiovascular Prevention, LMU Munich, Munich, Germany
| | - Renske J De Jong
- Institute for Cardiovascular Prevention, LMU Munich, Munich, Germany
| | - Janine Winter
- Institute for Cardiovascular Prevention, LMU Munich, Munich, Germany
| | - Andreas Schober
- Institute for Cardiovascular Prevention, LMU Munich, Munich, Germany
| | - Christian Weber
- Institute for Cardiovascular Prevention, LMU Munich, Munich, Germany.,DZHK, Partner Site Munich Heart Alliance, Munich, Germany
| | - Kamran Atabai
- Department of Medicine, Cardiovascular Research Institute, Lung Biology Center, University of California, San Francisco, California, United States
| | - Oliver Soehnlein
- Institute for Cardiovascular Prevention, LMU Munich, Munich, Germany.,Department of Pathology, Academic Medical Center, Amsterdam University, The Netherlands.,DZHK, Partner Site Munich Heart Alliance, Munich, Germany.,Department of Physiology and Pharmacology (FyFa), Karolinska Institutet, Stockholm, Sweden.,Department of Medicine, Karolinska Institutet, Stockholm, Sweden
| |
Collapse
|
6
|
Paulin N, Döring Y, Kooijman S, Blanchet X, Viola JR, de Jong R, Mandl M, Hendrikse J, Schiener M, von Hundelshausen P, Vogt A, Weber C, Bdeir K, Hofmann SM, Rensen PCN, Drechsler M, Soehnlein O. Human Neutrophil Peptide 1 Limits Hypercholesterolemia-induced Atherosclerosis by Increasing Hepatic LDL Clearance. EBioMedicine 2017; 16:204-211. [PMID: 28111237 PMCID: PMC5474437 DOI: 10.1016/j.ebiom.2017.01.006] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2016] [Revised: 01/05/2017] [Accepted: 01/05/2017] [Indexed: 11/20/2022] Open
Abstract
Increases in plasma LDL-cholesterol have unequivocally been established as a causal risk factor for atherosclerosis. Hence, strategies for lowering of LDL-cholesterol may have immediate therapeutic relevance. Here we study the role of human neutrophil peptide 1 (HNP1) in a mouse model of atherosclerosis and identify its potent atheroprotective effect both upon transgenic overexpression and therapeutic delivery. The effect was found to be due to a reduction of plasma LDL-cholesterol. Mechanistically, HNP1 binds to apolipoproteins enriched in LDL. This interaction facilitates clearance of LDL particles in the liver via LDL receptor. Thus, we here identify a non-redundant mechanism by which HNP1 allows for reduction of LDL-cholesterol, a process that may be therapeutically instructed to lower cardiovascular risk. Mice with transgenic expression of human neutrophil peptide 1 (HNP1) exhibit lower plasma VLDL/LDL levels and smaller atherosclerotic lesion sizes. Repetitive HNP1 delivery is atheroprotective by reducing hypercholesterolemia. HNP1 binds to apolipoproteins in LDL and facilitates LDL clearance in the liver involving LDL receptor.
Increased plasma lipid levels (i.e. hypercholesterolemia) are a primary risk factor for atherosclerosis, the pathology underlying myocardial infarction and stroke. Here we show that human neutrophil peptide 1 (HNP1, also known as α-defensin), an antimicrobial protein typically released from activated neutrophils, binds to apolipoproteins within plasma lipoproteins and facilitates the clearance of plasma lipids in the liver. As a consequence, repeated injection of hypercholesterolemic mice with HNP1 reduces atherosclerotic lesion formation. Thus, this study provides an innovative strategy to reduce hypercholesterolemia and hence a way to potentially reduce cardiovascular risk.
Collapse
MESH Headings
- Animals
- Apolipoproteins/blood
- Apolipoproteins/metabolism
- Atherosclerosis/genetics
- Atherosclerosis/metabolism
- Atherosclerosis/prevention & control
- Cholesterol, LDL/blood
- Cholesterol, LDL/metabolism
- Female
- Hep G2 Cells
- Humans
- Hypercholesterolemia/genetics
- Hypercholesterolemia/metabolism
- Hypercholesterolemia/prevention & control
- Immunohistochemistry
- Lipoproteins, LDL/blood
- Lipoproteins, LDL/metabolism
- Lipoproteins, LDL/pharmacokinetics
- Liver/drug effects
- Liver/metabolism
- Mice, Inbred C57BL
- Mice, Knockout
- Mice, Transgenic
- Microscopy, Confocal
- Protein Binding
- RNA Interference
- Receptors, LDL/genetics
- Receptors, LDL/metabolism
- alpha-Defensins/administration & dosage
- alpha-Defensins/genetics
- alpha-Defensins/metabolism
Collapse
Affiliation(s)
- Nicole Paulin
- Institute for Cardiovascular Prevention (IPEK), LMU Munich, Munich 80336, Germany
| | - Yvonne Döring
- Institute for Cardiovascular Prevention (IPEK), LMU Munich, Munich 80336, Germany
| | - Sander Kooijman
- Department of Medicine, Division of Endocrinology, Leiden University Medical Center, 2300 RC Leiden, The Netherlands; Einthoven Laboratory for Vascular Medicine, Leiden University Medical Center, 2300 RC Leiden, The Netherlands
| | - Xavier Blanchet
- Institute for Cardiovascular Prevention (IPEK), LMU Munich, Munich 80336, Germany
| | - Joana R Viola
- Institute for Cardiovascular Prevention (IPEK), LMU Munich, Munich 80336, Germany; Department of Pathology, AMC, 1105 AZ Amsterdam, The Netherlands
| | - Renske de Jong
- Institute for Cardiovascular Prevention (IPEK), LMU Munich, Munich 80336, Germany; Department of Pathology, AMC, 1105 AZ Amsterdam, The Netherlands
| | - Manuela Mandl
- Institute for Cardiovascular Prevention (IPEK), LMU Munich, Munich 80336, Germany
| | - Jeffrey Hendrikse
- Institute for Cardiovascular Prevention (IPEK), LMU Munich, Munich 80336, Germany; Department of Pathology, AMC, 1105 AZ Amsterdam, The Netherlands
| | - Maximilian Schiener
- Institute for Cardiovascular Prevention (IPEK), LMU Munich, Munich 80336, Germany
| | | | - Anja Vogt
- Medizinische Klinik und Poliklinik IV, Klinikum der LMU München, Munich 80336, Germany
| | - Christian Weber
- Institute for Cardiovascular Prevention (IPEK), LMU Munich, Munich 80336, Germany; DZHK, Partner Site Munich Heart Alliance, Munich 80336, Germany
| | - Khalil Bdeir
- Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
| | - Susanna M Hofmann
- Medizinische Klinik und Poliklinik IV, Klinikum der LMU München, Munich 80336, Germany; Institute for Diabetes and Regeneration, Helmholtz Center Munich, Germany; German Center for Diabetes Research (DZD) München-Neuherberg, Germany
| | - Patrick C N Rensen
- Department of Medicine, Division of Endocrinology, Leiden University Medical Center, 2300 RC Leiden, The Netherlands; Einthoven Laboratory for Vascular Medicine, Leiden University Medical Center, 2300 RC Leiden, The Netherlands
| | - Maik Drechsler
- Institute for Cardiovascular Prevention (IPEK), LMU Munich, Munich 80336, Germany; Department of Pathology, AMC, 1105 AZ Amsterdam, The Netherlands; DZHK, Partner Site Munich Heart Alliance, Munich 80336, Germany
| | - Oliver Soehnlein
- Institute for Cardiovascular Prevention (IPEK), LMU Munich, Munich 80336, Germany; Department of Pathology, AMC, 1105 AZ Amsterdam, The Netherlands; DZHK, Partner Site Munich Heart Alliance, Munich 80336, Germany.
| |
Collapse
|
7
|
de Jong RJ, Paulin N, Lemnitzer P, Viola JR, Winter C, Ferraro B, Grommes J, Weber C, Reutelingsperger C, Drechsler M, Soehnlein O. Protective Aptitude of Annexin A1 in Arterial Neointima Formation in Atherosclerosis-Prone Mice-Brief Report. Arterioscler Thromb Vasc Biol 2016; 37:312-315. [PMID: 28062503 DOI: 10.1161/atvbaha.116.308744] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2016] [Accepted: 12/19/2016] [Indexed: 11/16/2022]
Abstract
OBJECTIVE Restenosis as a consequence of arterial injury is aggravated by inflammatory pathways. Here, we investigate the role of the proresolving protein annexin A1 (AnxA1) in healing after wire injury. APPROACH AND RESULTS Apoe-/- and Apoe-/-Anxa1-/- mice were subjected to wire injury while fed a high-cholesterol diet. Subsequently, localization of AnxA1 and AnxA1 plasma levels were examined. AnxA1 was found to localize within endothelial cells and macrophages in the neointima. Levels of AnxA1 in the plasma and its lesional expression negatively correlated with neointima size, and in the absence of AnxA1, neointima formation was aggravated by the accumulation and proliferation of macrophages. In contrast, reendothelialization and smooth muscle cell infiltration were not affected in Apoe-/-Anxa1-/- mice. CONCLUSIONS AnxA1 is protective in healing after wire injury and could, therefore, be an attractive therapeutic compound to prevent from restenosis after vascular damage.
Collapse
Affiliation(s)
- Renske J de Jong
- From the IPEK, LMU Munich, Germany (R.J.d.J., N.P., P.L., J.R.V., C. Winter, B.F., J.G., C. Weber, M.D., O.S.); Department of Pathology, AMC, Amsterdam University, The Netherlands (R.J.d.J., J.R.V., M.D., O.S.); Department of Experimental Medicine, Second University of Naples, Italy (B.F.); European Vascular Center Aachen-Maastricht, University Hospital RWTH Aachen, Germany (J.G.); Department of Biochemistry, CARIM, Maastricht University, The Netherlands (C. Weber, C.R.); and DZHK, partner site Munich Heart Alliance, Germany (C. Weber, M.D., O.S.)
| | - Nicole Paulin
- From the IPEK, LMU Munich, Germany (R.J.d.J., N.P., P.L., J.R.V., C. Winter, B.F., J.G., C. Weber, M.D., O.S.); Department of Pathology, AMC, Amsterdam University, The Netherlands (R.J.d.J., J.R.V., M.D., O.S.); Department of Experimental Medicine, Second University of Naples, Italy (B.F.); European Vascular Center Aachen-Maastricht, University Hospital RWTH Aachen, Germany (J.G.); Department of Biochemistry, CARIM, Maastricht University, The Netherlands (C. Weber, C.R.); and DZHK, partner site Munich Heart Alliance, Germany (C. Weber, M.D., O.S.)
| | - Patricia Lemnitzer
- From the IPEK, LMU Munich, Germany (R.J.d.J., N.P., P.L., J.R.V., C. Winter, B.F., J.G., C. Weber, M.D., O.S.); Department of Pathology, AMC, Amsterdam University, The Netherlands (R.J.d.J., J.R.V., M.D., O.S.); Department of Experimental Medicine, Second University of Naples, Italy (B.F.); European Vascular Center Aachen-Maastricht, University Hospital RWTH Aachen, Germany (J.G.); Department of Biochemistry, CARIM, Maastricht University, The Netherlands (C. Weber, C.R.); and DZHK, partner site Munich Heart Alliance, Germany (C. Weber, M.D., O.S.)
| | - Joana R Viola
- From the IPEK, LMU Munich, Germany (R.J.d.J., N.P., P.L., J.R.V., C. Winter, B.F., J.G., C. Weber, M.D., O.S.); Department of Pathology, AMC, Amsterdam University, The Netherlands (R.J.d.J., J.R.V., M.D., O.S.); Department of Experimental Medicine, Second University of Naples, Italy (B.F.); European Vascular Center Aachen-Maastricht, University Hospital RWTH Aachen, Germany (J.G.); Department of Biochemistry, CARIM, Maastricht University, The Netherlands (C. Weber, C.R.); and DZHK, partner site Munich Heart Alliance, Germany (C. Weber, M.D., O.S.)
| | - Carla Winter
- From the IPEK, LMU Munich, Germany (R.J.d.J., N.P., P.L., J.R.V., C. Winter, B.F., J.G., C. Weber, M.D., O.S.); Department of Pathology, AMC, Amsterdam University, The Netherlands (R.J.d.J., J.R.V., M.D., O.S.); Department of Experimental Medicine, Second University of Naples, Italy (B.F.); European Vascular Center Aachen-Maastricht, University Hospital RWTH Aachen, Germany (J.G.); Department of Biochemistry, CARIM, Maastricht University, The Netherlands (C. Weber, C.R.); and DZHK, partner site Munich Heart Alliance, Germany (C. Weber, M.D., O.S.)
| | - Bartolo Ferraro
- From the IPEK, LMU Munich, Germany (R.J.d.J., N.P., P.L., J.R.V., C. Winter, B.F., J.G., C. Weber, M.D., O.S.); Department of Pathology, AMC, Amsterdam University, The Netherlands (R.J.d.J., J.R.V., M.D., O.S.); Department of Experimental Medicine, Second University of Naples, Italy (B.F.); European Vascular Center Aachen-Maastricht, University Hospital RWTH Aachen, Germany (J.G.); Department of Biochemistry, CARIM, Maastricht University, The Netherlands (C. Weber, C.R.); and DZHK, partner site Munich Heart Alliance, Germany (C. Weber, M.D., O.S.)
| | - Jochen Grommes
- From the IPEK, LMU Munich, Germany (R.J.d.J., N.P., P.L., J.R.V., C. Winter, B.F., J.G., C. Weber, M.D., O.S.); Department of Pathology, AMC, Amsterdam University, The Netherlands (R.J.d.J., J.R.V., M.D., O.S.); Department of Experimental Medicine, Second University of Naples, Italy (B.F.); European Vascular Center Aachen-Maastricht, University Hospital RWTH Aachen, Germany (J.G.); Department of Biochemistry, CARIM, Maastricht University, The Netherlands (C. Weber, C.R.); and DZHK, partner site Munich Heart Alliance, Germany (C. Weber, M.D., O.S.)
| | - Christian Weber
- From the IPEK, LMU Munich, Germany (R.J.d.J., N.P., P.L., J.R.V., C. Winter, B.F., J.G., C. Weber, M.D., O.S.); Department of Pathology, AMC, Amsterdam University, The Netherlands (R.J.d.J., J.R.V., M.D., O.S.); Department of Experimental Medicine, Second University of Naples, Italy (B.F.); European Vascular Center Aachen-Maastricht, University Hospital RWTH Aachen, Germany (J.G.); Department of Biochemistry, CARIM, Maastricht University, The Netherlands (C. Weber, C.R.); and DZHK, partner site Munich Heart Alliance, Germany (C. Weber, M.D., O.S.)
| | - Chris Reutelingsperger
- From the IPEK, LMU Munich, Germany (R.J.d.J., N.P., P.L., J.R.V., C. Winter, B.F., J.G., C. Weber, M.D., O.S.); Department of Pathology, AMC, Amsterdam University, The Netherlands (R.J.d.J., J.R.V., M.D., O.S.); Department of Experimental Medicine, Second University of Naples, Italy (B.F.); European Vascular Center Aachen-Maastricht, University Hospital RWTH Aachen, Germany (J.G.); Department of Biochemistry, CARIM, Maastricht University, The Netherlands (C. Weber, C.R.); and DZHK, partner site Munich Heart Alliance, Germany (C. Weber, M.D., O.S.)
| | - Maik Drechsler
- From the IPEK, LMU Munich, Germany (R.J.d.J., N.P., P.L., J.R.V., C. Winter, B.F., J.G., C. Weber, M.D., O.S.); Department of Pathology, AMC, Amsterdam University, The Netherlands (R.J.d.J., J.R.V., M.D., O.S.); Department of Experimental Medicine, Second University of Naples, Italy (B.F.); European Vascular Center Aachen-Maastricht, University Hospital RWTH Aachen, Germany (J.G.); Department of Biochemistry, CARIM, Maastricht University, The Netherlands (C. Weber, C.R.); and DZHK, partner site Munich Heart Alliance, Germany (C. Weber, M.D., O.S.)
| | - Oliver Soehnlein
- From the IPEK, LMU Munich, Germany (R.J.d.J., N.P., P.L., J.R.V., C. Winter, B.F., J.G., C. Weber, M.D., O.S.); Department of Pathology, AMC, Amsterdam University, The Netherlands (R.J.d.J., J.R.V., M.D., O.S.); Department of Experimental Medicine, Second University of Naples, Italy (B.F.); European Vascular Center Aachen-Maastricht, University Hospital RWTH Aachen, Germany (J.G.); Department of Biochemistry, CARIM, Maastricht University, The Netherlands (C. Weber, C.R.); and DZHK, partner site Munich Heart Alliance, Germany (C. Weber, M.D., O.S.).
| |
Collapse
|
8
|
Viola JR, Lemnitzer P, Jansen Y, Csaba G, Winter C, Neideck C, Silvestre-Roig C, Dittmar G, Döring Y, Drechsler M, Weber C, Zimmer R, Cenac N, Soehnlein O. Resolving Lipid Mediators Maresin 1 and Resolvin D2 Prevent Atheroprogression in Mice. Circ Res 2016; 119:1030-1038. [PMID: 27531933 DOI: 10.1161/circresaha.116.309492] [Citation(s) in RCA: 170] [Impact Index Per Article: 21.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/06/2016] [Accepted: 08/16/2016] [Indexed: 12/20/2022]
Abstract
RATIONALE Atheroprogression is a consequence of nonresolved inflammation, and currently a comprehensive overview of the mechanisms preventing resolution is missing. However, in acute inflammation, resolution is known to be orchestrated by a switch from inflammatory to resolving lipid mediators. Therefore, we hypothesized that lesional lipid mediator imbalance favors atheroprogression. OBJECTIVE To understand the lipid mediator balance during atheroprogression and to establish an interventional strategy based on the delivery of resolving lipid mediators. METHODS AND RESULTS Aortic lipid mediator profiling of aortas from Apoe-/- mice fed a high-fat diet for 4 weeks, 8 weeks, or 4 months revealed an expansion of inflammatory lipid mediators, Leukotriene B4 and Prostaglandin E2, and a concomitant decrease of resolving lipid mediators, Resolvin D2 (RvD2) and Maresin 1 (MaR1), during advanced atherosclerosis. Functionally, aortic Leukotriene B4 and Prostaglandin E2 levels correlated with traits of plaque instability, whereas RvD2 and MaR1 levels correlated with the signs of plaque stability. In a therapeutic context, repetitive RvD2 and MaR1 delivery prevented atheroprogression as characterized by halted expansion of the necrotic core and accumulation of macrophages along with increased fibrous cap thickness and smooth muscle cell numbers. Mechanistically, RvD2 and MaR1 induced a shift in macrophage profile toward a reparative phenotype, which secondarily stimulated collagen synthesis in smooth muscle cells. CONCLUSIONS We present evidence for the imbalance between inflammatory and resolving lipid mediators during atheroprogression. Delivery of RvD2 and MaR1 successfully prevented atheroprogression, suggesting that resolving lipid mediators potentially represent an innovative strategy to resolve arterial inflammation.
Collapse
Affiliation(s)
- Joana R Viola
- From the Institute for Cardiovascular Prevention (IPEK), LMU Munich, Germany (J.R.V., P.L., Y.J., C.W., C.N., C.S.-R., Y.D., M.D., C.W., O.S.); Department of Pathology, Academic Medical Center (AMC), Amsterdam University, The Netherlands (J.R.V., C.S.-R., M.D., O.S.); Department of Informatics, Institute of Bioinformatics, LMU Munich, Germany (G.C., R.Z.); DZHK, Partner Site Munich Heart Alliance, Germany (C.W., Y.D., M.D., C.W., O.S.); Mass Spectrometry Core Facility, Max-Delbrück Center, Berlin Institute of Health, Germany (G.D.); and Inserm U1043, CHU Purpan, Toulouse, France (N.C.)
| | - Patricia Lemnitzer
- From the Institute for Cardiovascular Prevention (IPEK), LMU Munich, Germany (J.R.V., P.L., Y.J., C.W., C.N., C.S.-R., Y.D., M.D., C.W., O.S.); Department of Pathology, Academic Medical Center (AMC), Amsterdam University, The Netherlands (J.R.V., C.S.-R., M.D., O.S.); Department of Informatics, Institute of Bioinformatics, LMU Munich, Germany (G.C., R.Z.); DZHK, Partner Site Munich Heart Alliance, Germany (C.W., Y.D., M.D., C.W., O.S.); Mass Spectrometry Core Facility, Max-Delbrück Center, Berlin Institute of Health, Germany (G.D.); and Inserm U1043, CHU Purpan, Toulouse, France (N.C.)
| | - Yvonne Jansen
- From the Institute for Cardiovascular Prevention (IPEK), LMU Munich, Germany (J.R.V., P.L., Y.J., C.W., C.N., C.S.-R., Y.D., M.D., C.W., O.S.); Department of Pathology, Academic Medical Center (AMC), Amsterdam University, The Netherlands (J.R.V., C.S.-R., M.D., O.S.); Department of Informatics, Institute of Bioinformatics, LMU Munich, Germany (G.C., R.Z.); DZHK, Partner Site Munich Heart Alliance, Germany (C.W., Y.D., M.D., C.W., O.S.); Mass Spectrometry Core Facility, Max-Delbrück Center, Berlin Institute of Health, Germany (G.D.); and Inserm U1043, CHU Purpan, Toulouse, France (N.C.)
| | - Gergely Csaba
- From the Institute for Cardiovascular Prevention (IPEK), LMU Munich, Germany (J.R.V., P.L., Y.J., C.W., C.N., C.S.-R., Y.D., M.D., C.W., O.S.); Department of Pathology, Academic Medical Center (AMC), Amsterdam University, The Netherlands (J.R.V., C.S.-R., M.D., O.S.); Department of Informatics, Institute of Bioinformatics, LMU Munich, Germany (G.C., R.Z.); DZHK, Partner Site Munich Heart Alliance, Germany (C.W., Y.D., M.D., C.W., O.S.); Mass Spectrometry Core Facility, Max-Delbrück Center, Berlin Institute of Health, Germany (G.D.); and Inserm U1043, CHU Purpan, Toulouse, France (N.C.)
| | - Carla Winter
- From the Institute for Cardiovascular Prevention (IPEK), LMU Munich, Germany (J.R.V., P.L., Y.J., C.W., C.N., C.S.-R., Y.D., M.D., C.W., O.S.); Department of Pathology, Academic Medical Center (AMC), Amsterdam University, The Netherlands (J.R.V., C.S.-R., M.D., O.S.); Department of Informatics, Institute of Bioinformatics, LMU Munich, Germany (G.C., R.Z.); DZHK, Partner Site Munich Heart Alliance, Germany (C.W., Y.D., M.D., C.W., O.S.); Mass Spectrometry Core Facility, Max-Delbrück Center, Berlin Institute of Health, Germany (G.D.); and Inserm U1043, CHU Purpan, Toulouse, France (N.C.)
| | - Carlos Neideck
- From the Institute for Cardiovascular Prevention (IPEK), LMU Munich, Germany (J.R.V., P.L., Y.J., C.W., C.N., C.S.-R., Y.D., M.D., C.W., O.S.); Department of Pathology, Academic Medical Center (AMC), Amsterdam University, The Netherlands (J.R.V., C.S.-R., M.D., O.S.); Department of Informatics, Institute of Bioinformatics, LMU Munich, Germany (G.C., R.Z.); DZHK, Partner Site Munich Heart Alliance, Germany (C.W., Y.D., M.D., C.W., O.S.); Mass Spectrometry Core Facility, Max-Delbrück Center, Berlin Institute of Health, Germany (G.D.); and Inserm U1043, CHU Purpan, Toulouse, France (N.C.)
| | - Carlos Silvestre-Roig
- From the Institute for Cardiovascular Prevention (IPEK), LMU Munich, Germany (J.R.V., P.L., Y.J., C.W., C.N., C.S.-R., Y.D., M.D., C.W., O.S.); Department of Pathology, Academic Medical Center (AMC), Amsterdam University, The Netherlands (J.R.V., C.S.-R., M.D., O.S.); Department of Informatics, Institute of Bioinformatics, LMU Munich, Germany (G.C., R.Z.); DZHK, Partner Site Munich Heart Alliance, Germany (C.W., Y.D., M.D., C.W., O.S.); Mass Spectrometry Core Facility, Max-Delbrück Center, Berlin Institute of Health, Germany (G.D.); and Inserm U1043, CHU Purpan, Toulouse, France (N.C.)
| | - Gunnar Dittmar
- From the Institute for Cardiovascular Prevention (IPEK), LMU Munich, Germany (J.R.V., P.L., Y.J., C.W., C.N., C.S.-R., Y.D., M.D., C.W., O.S.); Department of Pathology, Academic Medical Center (AMC), Amsterdam University, The Netherlands (J.R.V., C.S.-R., M.D., O.S.); Department of Informatics, Institute of Bioinformatics, LMU Munich, Germany (G.C., R.Z.); DZHK, Partner Site Munich Heart Alliance, Germany (C.W., Y.D., M.D., C.W., O.S.); Mass Spectrometry Core Facility, Max-Delbrück Center, Berlin Institute of Health, Germany (G.D.); and Inserm U1043, CHU Purpan, Toulouse, France (N.C.)
| | - Yvonne Döring
- From the Institute for Cardiovascular Prevention (IPEK), LMU Munich, Germany (J.R.V., P.L., Y.J., C.W., C.N., C.S.-R., Y.D., M.D., C.W., O.S.); Department of Pathology, Academic Medical Center (AMC), Amsterdam University, The Netherlands (J.R.V., C.S.-R., M.D., O.S.); Department of Informatics, Institute of Bioinformatics, LMU Munich, Germany (G.C., R.Z.); DZHK, Partner Site Munich Heart Alliance, Germany (C.W., Y.D., M.D., C.W., O.S.); Mass Spectrometry Core Facility, Max-Delbrück Center, Berlin Institute of Health, Germany (G.D.); and Inserm U1043, CHU Purpan, Toulouse, France (N.C.)
| | - Maik Drechsler
- From the Institute for Cardiovascular Prevention (IPEK), LMU Munich, Germany (J.R.V., P.L., Y.J., C.W., C.N., C.S.-R., Y.D., M.D., C.W., O.S.); Department of Pathology, Academic Medical Center (AMC), Amsterdam University, The Netherlands (J.R.V., C.S.-R., M.D., O.S.); Department of Informatics, Institute of Bioinformatics, LMU Munich, Germany (G.C., R.Z.); DZHK, Partner Site Munich Heart Alliance, Germany (C.W., Y.D., M.D., C.W., O.S.); Mass Spectrometry Core Facility, Max-Delbrück Center, Berlin Institute of Health, Germany (G.D.); and Inserm U1043, CHU Purpan, Toulouse, France (N.C.)
| | - Christian Weber
- From the Institute for Cardiovascular Prevention (IPEK), LMU Munich, Germany (J.R.V., P.L., Y.J., C.W., C.N., C.S.-R., Y.D., M.D., C.W., O.S.); Department of Pathology, Academic Medical Center (AMC), Amsterdam University, The Netherlands (J.R.V., C.S.-R., M.D., O.S.); Department of Informatics, Institute of Bioinformatics, LMU Munich, Germany (G.C., R.Z.); DZHK, Partner Site Munich Heart Alliance, Germany (C.W., Y.D., M.D., C.W., O.S.); Mass Spectrometry Core Facility, Max-Delbrück Center, Berlin Institute of Health, Germany (G.D.); and Inserm U1043, CHU Purpan, Toulouse, France (N.C.)
| | - Ralf Zimmer
- From the Institute for Cardiovascular Prevention (IPEK), LMU Munich, Germany (J.R.V., P.L., Y.J., C.W., C.N., C.S.-R., Y.D., M.D., C.W., O.S.); Department of Pathology, Academic Medical Center (AMC), Amsterdam University, The Netherlands (J.R.V., C.S.-R., M.D., O.S.); Department of Informatics, Institute of Bioinformatics, LMU Munich, Germany (G.C., R.Z.); DZHK, Partner Site Munich Heart Alliance, Germany (C.W., Y.D., M.D., C.W., O.S.); Mass Spectrometry Core Facility, Max-Delbrück Center, Berlin Institute of Health, Germany (G.D.); and Inserm U1043, CHU Purpan, Toulouse, France (N.C.)
| | - Nicolas Cenac
- From the Institute for Cardiovascular Prevention (IPEK), LMU Munich, Germany (J.R.V., P.L., Y.J., C.W., C.N., C.S.-R., Y.D., M.D., C.W., O.S.); Department of Pathology, Academic Medical Center (AMC), Amsterdam University, The Netherlands (J.R.V., C.S.-R., M.D., O.S.); Department of Informatics, Institute of Bioinformatics, LMU Munich, Germany (G.C., R.Z.); DZHK, Partner Site Munich Heart Alliance, Germany (C.W., Y.D., M.D., C.W., O.S.); Mass Spectrometry Core Facility, Max-Delbrück Center, Berlin Institute of Health, Germany (G.D.); and Inserm U1043, CHU Purpan, Toulouse, France (N.C.)
| | - Oliver Soehnlein
- From the Institute for Cardiovascular Prevention (IPEK), LMU Munich, Germany (J.R.V., P.L., Y.J., C.W., C.N., C.S.-R., Y.D., M.D., C.W., O.S.); Department of Pathology, Academic Medical Center (AMC), Amsterdam University, The Netherlands (J.R.V., C.S.-R., M.D., O.S.); Department of Informatics, Institute of Bioinformatics, LMU Munich, Germany (G.C., R.Z.); DZHK, Partner Site Munich Heart Alliance, Germany (C.W., Y.D., M.D., C.W., O.S.); Mass Spectrometry Core Facility, Max-Delbrück Center, Berlin Institute of Health, Germany (G.D.); and Inserm U1043, CHU Purpan, Toulouse, France (N.C.).
| |
Collapse
|
9
|
Drechsler M, de Jong R, Rossaint J, Viola JR, Leoni G, Wang JM, Grommes J, Hinkel R, Kupatt C, Weber C, Döring Y, Zarbock A, Soehnlein O. Annexin A1 counteracts chemokine-induced arterial myeloid cell recruitment. Circ Res 2014; 116:827-35. [PMID: 25520364 DOI: 10.1161/circresaha.116.305825] [Citation(s) in RCA: 117] [Impact Index Per Article: 11.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
RATIONALE Chemokine-controlled arterial leukocyte recruitment is a crucial process in atherosclerosis. Formyl peptide receptor 2 (FPR2) is a chemoattractant receptor that recognizes proinflammatory and proresolving ligands. The contribution of FPR2 and its proresolving ligand annexin A1 to atherosclerotic lesion formation is largely undefined. OBJECTIVE Because of the ambivalence of FPR2 ligands, we here investigate the role of FPR2 and its resolving ligand annexin A1 in atherogenesis. METHODS AND RESULTS Deletion of FPR2 or its ligand annexin A1 enhances atherosclerotic lesion formation, arterial myeloid cell adhesion, and recruitment. Mechanistically, we identify annexin A1 as an endogenous inhibitor of integrin activation evoked by the chemokines CCL5, CCL2, and CXCL1. Specifically, the annexin A1 fragment Ac2-26 counteracts conformational activation and clustering of integrins on myeloid cells evoked by CCL5, CCL2, and CXCL1 through inhibiting activation of the small GTPase Rap1. In vivo administration of Ac2-26 largely diminishes arterial recruitment of myeloid cells in a FPR2-dependent fashion. This effect is also observed in the presence of selective antagonists to CCR5, CCR2, or CXCR2, whereas Ac2-26 was without effect when all 3 chemokine receptors were antagonized simultaneously. Finally, repeated treatment with Ac2-26 reduces atherosclerotic lesion sizes and lesional macrophage accumulation. CONCLUSIONS Instructing the annexin A1-FPR2 axis harbors a novel approach to target arterial leukocyte recruitment. With the ability of Ac2-26 to counteract integrin activation exerted by various chemokines, delivery of Ac2-26 may be superior in inhibition of arterial leukocyte recruitment when compared with blocking individual chemokine receptors.
Collapse
Affiliation(s)
- Maik Drechsler
- From the Institute for Cardiovascular Prevention (IPEK), LMU Munich, Munich, Germany (M.D., R.d.J., J.R.V., G.L., J.G., C.W., Y.D., O.S.); Department of Pathology, Academic Medical Center (AMC), Amsterdam University, Amsterdam, The Netherlands (M.D., O.S.); Department of Anaesthesiology, University Münster, Münster, Germany (J.R., A.Z.); Max Planck Institute, Münster, Germany (J.R., A.Z.); Laboratory of Molecular Immunoregulation, NCI, Frederick, MD (J.M.W.); European Vascular Center Aachen-Maastricht, University Hospital RWTH Aachen, Aachen, Germany (J.G.); Medizinische Klinik und Poliklinik I, Klinikum Großhadern, LMU Munich, Munich, Germany (R.H., C.K.); and DZHK, Partner Site Munich Heart Alliance, Munich, Germany (R.H., C.K., C.W., O.S.)
| | - Renske de Jong
- From the Institute for Cardiovascular Prevention (IPEK), LMU Munich, Munich, Germany (M.D., R.d.J., J.R.V., G.L., J.G., C.W., Y.D., O.S.); Department of Pathology, Academic Medical Center (AMC), Amsterdam University, Amsterdam, The Netherlands (M.D., O.S.); Department of Anaesthesiology, University Münster, Münster, Germany (J.R., A.Z.); Max Planck Institute, Münster, Germany (J.R., A.Z.); Laboratory of Molecular Immunoregulation, NCI, Frederick, MD (J.M.W.); European Vascular Center Aachen-Maastricht, University Hospital RWTH Aachen, Aachen, Germany (J.G.); Medizinische Klinik und Poliklinik I, Klinikum Großhadern, LMU Munich, Munich, Germany (R.H., C.K.); and DZHK, Partner Site Munich Heart Alliance, Munich, Germany (R.H., C.K., C.W., O.S.)
| | - Jan Rossaint
- From the Institute for Cardiovascular Prevention (IPEK), LMU Munich, Munich, Germany (M.D., R.d.J., J.R.V., G.L., J.G., C.W., Y.D., O.S.); Department of Pathology, Academic Medical Center (AMC), Amsterdam University, Amsterdam, The Netherlands (M.D., O.S.); Department of Anaesthesiology, University Münster, Münster, Germany (J.R., A.Z.); Max Planck Institute, Münster, Germany (J.R., A.Z.); Laboratory of Molecular Immunoregulation, NCI, Frederick, MD (J.M.W.); European Vascular Center Aachen-Maastricht, University Hospital RWTH Aachen, Aachen, Germany (J.G.); Medizinische Klinik und Poliklinik I, Klinikum Großhadern, LMU Munich, Munich, Germany (R.H., C.K.); and DZHK, Partner Site Munich Heart Alliance, Munich, Germany (R.H., C.K., C.W., O.S.)
| | - Joana R Viola
- From the Institute for Cardiovascular Prevention (IPEK), LMU Munich, Munich, Germany (M.D., R.d.J., J.R.V., G.L., J.G., C.W., Y.D., O.S.); Department of Pathology, Academic Medical Center (AMC), Amsterdam University, Amsterdam, The Netherlands (M.D., O.S.); Department of Anaesthesiology, University Münster, Münster, Germany (J.R., A.Z.); Max Planck Institute, Münster, Germany (J.R., A.Z.); Laboratory of Molecular Immunoregulation, NCI, Frederick, MD (J.M.W.); European Vascular Center Aachen-Maastricht, University Hospital RWTH Aachen, Aachen, Germany (J.G.); Medizinische Klinik und Poliklinik I, Klinikum Großhadern, LMU Munich, Munich, Germany (R.H., C.K.); and DZHK, Partner Site Munich Heart Alliance, Munich, Germany (R.H., C.K., C.W., O.S.)
| | - Giovanna Leoni
- From the Institute for Cardiovascular Prevention (IPEK), LMU Munich, Munich, Germany (M.D., R.d.J., J.R.V., G.L., J.G., C.W., Y.D., O.S.); Department of Pathology, Academic Medical Center (AMC), Amsterdam University, Amsterdam, The Netherlands (M.D., O.S.); Department of Anaesthesiology, University Münster, Münster, Germany (J.R., A.Z.); Max Planck Institute, Münster, Germany (J.R., A.Z.); Laboratory of Molecular Immunoregulation, NCI, Frederick, MD (J.M.W.); European Vascular Center Aachen-Maastricht, University Hospital RWTH Aachen, Aachen, Germany (J.G.); Medizinische Klinik und Poliklinik I, Klinikum Großhadern, LMU Munich, Munich, Germany (R.H., C.K.); and DZHK, Partner Site Munich Heart Alliance, Munich, Germany (R.H., C.K., C.W., O.S.)
| | - Ji Ming Wang
- From the Institute for Cardiovascular Prevention (IPEK), LMU Munich, Munich, Germany (M.D., R.d.J., J.R.V., G.L., J.G., C.W., Y.D., O.S.); Department of Pathology, Academic Medical Center (AMC), Amsterdam University, Amsterdam, The Netherlands (M.D., O.S.); Department of Anaesthesiology, University Münster, Münster, Germany (J.R., A.Z.); Max Planck Institute, Münster, Germany (J.R., A.Z.); Laboratory of Molecular Immunoregulation, NCI, Frederick, MD (J.M.W.); European Vascular Center Aachen-Maastricht, University Hospital RWTH Aachen, Aachen, Germany (J.G.); Medizinische Klinik und Poliklinik I, Klinikum Großhadern, LMU Munich, Munich, Germany (R.H., C.K.); and DZHK, Partner Site Munich Heart Alliance, Munich, Germany (R.H., C.K., C.W., O.S.)
| | - Jochen Grommes
- From the Institute for Cardiovascular Prevention (IPEK), LMU Munich, Munich, Germany (M.D., R.d.J., J.R.V., G.L., J.G., C.W., Y.D., O.S.); Department of Pathology, Academic Medical Center (AMC), Amsterdam University, Amsterdam, The Netherlands (M.D., O.S.); Department of Anaesthesiology, University Münster, Münster, Germany (J.R., A.Z.); Max Planck Institute, Münster, Germany (J.R., A.Z.); Laboratory of Molecular Immunoregulation, NCI, Frederick, MD (J.M.W.); European Vascular Center Aachen-Maastricht, University Hospital RWTH Aachen, Aachen, Germany (J.G.); Medizinische Klinik und Poliklinik I, Klinikum Großhadern, LMU Munich, Munich, Germany (R.H., C.K.); and DZHK, Partner Site Munich Heart Alliance, Munich, Germany (R.H., C.K., C.W., O.S.)
| | - Rabea Hinkel
- From the Institute for Cardiovascular Prevention (IPEK), LMU Munich, Munich, Germany (M.D., R.d.J., J.R.V., G.L., J.G., C.W., Y.D., O.S.); Department of Pathology, Academic Medical Center (AMC), Amsterdam University, Amsterdam, The Netherlands (M.D., O.S.); Department of Anaesthesiology, University Münster, Münster, Germany (J.R., A.Z.); Max Planck Institute, Münster, Germany (J.R., A.Z.); Laboratory of Molecular Immunoregulation, NCI, Frederick, MD (J.M.W.); European Vascular Center Aachen-Maastricht, University Hospital RWTH Aachen, Aachen, Germany (J.G.); Medizinische Klinik und Poliklinik I, Klinikum Großhadern, LMU Munich, Munich, Germany (R.H., C.K.); and DZHK, Partner Site Munich Heart Alliance, Munich, Germany (R.H., C.K., C.W., O.S.)
| | - Christian Kupatt
- From the Institute for Cardiovascular Prevention (IPEK), LMU Munich, Munich, Germany (M.D., R.d.J., J.R.V., G.L., J.G., C.W., Y.D., O.S.); Department of Pathology, Academic Medical Center (AMC), Amsterdam University, Amsterdam, The Netherlands (M.D., O.S.); Department of Anaesthesiology, University Münster, Münster, Germany (J.R., A.Z.); Max Planck Institute, Münster, Germany (J.R., A.Z.); Laboratory of Molecular Immunoregulation, NCI, Frederick, MD (J.M.W.); European Vascular Center Aachen-Maastricht, University Hospital RWTH Aachen, Aachen, Germany (J.G.); Medizinische Klinik und Poliklinik I, Klinikum Großhadern, LMU Munich, Munich, Germany (R.H., C.K.); and DZHK, Partner Site Munich Heart Alliance, Munich, Germany (R.H., C.K., C.W., O.S.)
| | - Christian Weber
- From the Institute for Cardiovascular Prevention (IPEK), LMU Munich, Munich, Germany (M.D., R.d.J., J.R.V., G.L., J.G., C.W., Y.D., O.S.); Department of Pathology, Academic Medical Center (AMC), Amsterdam University, Amsterdam, The Netherlands (M.D., O.S.); Department of Anaesthesiology, University Münster, Münster, Germany (J.R., A.Z.); Max Planck Institute, Münster, Germany (J.R., A.Z.); Laboratory of Molecular Immunoregulation, NCI, Frederick, MD (J.M.W.); European Vascular Center Aachen-Maastricht, University Hospital RWTH Aachen, Aachen, Germany (J.G.); Medizinische Klinik und Poliklinik I, Klinikum Großhadern, LMU Munich, Munich, Germany (R.H., C.K.); and DZHK, Partner Site Munich Heart Alliance, Munich, Germany (R.H., C.K., C.W., O.S.)
| | - Yvonne Döring
- From the Institute for Cardiovascular Prevention (IPEK), LMU Munich, Munich, Germany (M.D., R.d.J., J.R.V., G.L., J.G., C.W., Y.D., O.S.); Department of Pathology, Academic Medical Center (AMC), Amsterdam University, Amsterdam, The Netherlands (M.D., O.S.); Department of Anaesthesiology, University Münster, Münster, Germany (J.R., A.Z.); Max Planck Institute, Münster, Germany (J.R., A.Z.); Laboratory of Molecular Immunoregulation, NCI, Frederick, MD (J.M.W.); European Vascular Center Aachen-Maastricht, University Hospital RWTH Aachen, Aachen, Germany (J.G.); Medizinische Klinik und Poliklinik I, Klinikum Großhadern, LMU Munich, Munich, Germany (R.H., C.K.); and DZHK, Partner Site Munich Heart Alliance, Munich, Germany (R.H., C.K., C.W., O.S.)
| | - Alexander Zarbock
- From the Institute for Cardiovascular Prevention (IPEK), LMU Munich, Munich, Germany (M.D., R.d.J., J.R.V., G.L., J.G., C.W., Y.D., O.S.); Department of Pathology, Academic Medical Center (AMC), Amsterdam University, Amsterdam, The Netherlands (M.D., O.S.); Department of Anaesthesiology, University Münster, Münster, Germany (J.R., A.Z.); Max Planck Institute, Münster, Germany (J.R., A.Z.); Laboratory of Molecular Immunoregulation, NCI, Frederick, MD (J.M.W.); European Vascular Center Aachen-Maastricht, University Hospital RWTH Aachen, Aachen, Germany (J.G.); Medizinische Klinik und Poliklinik I, Klinikum Großhadern, LMU Munich, Munich, Germany (R.H., C.K.); and DZHK, Partner Site Munich Heart Alliance, Munich, Germany (R.H., C.K., C.W., O.S.)
| | - Oliver Soehnlein
- From the Institute for Cardiovascular Prevention (IPEK), LMU Munich, Munich, Germany (M.D., R.d.J., J.R.V., G.L., J.G., C.W., Y.D., O.S.); Department of Pathology, Academic Medical Center (AMC), Amsterdam University, Amsterdam, The Netherlands (M.D., O.S.); Department of Anaesthesiology, University Münster, Münster, Germany (J.R., A.Z.); Max Planck Institute, Münster, Germany (J.R., A.Z.); Laboratory of Molecular Immunoregulation, NCI, Frederick, MD (J.M.W.); European Vascular Center Aachen-Maastricht, University Hospital RWTH Aachen, Aachen, Germany (J.G.); Medizinische Klinik und Poliklinik I, Klinikum Großhadern, LMU Munich, Munich, Germany (R.H., C.K.); and DZHK, Partner Site Munich Heart Alliance, Munich, Germany (R.H., C.K., C.W., O.S.).
| |
Collapse
|
10
|
Oprea II, Viola JR, Moreno PMD, Simonson OE, Rodin S, Teller N, Tryggvason K, Lundin KE, Girnita L, Smith CIE. Repeatable, Inducible Micro-RNA-Based Technology Tightly Controls Liver Transgene Expression. Mol Ther Nucleic Acids 2014; 3:e172. [PMID: 24983837 PMCID: PMC4121515 DOI: 10.1038/mtna.2014.25] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/21/2014] [Accepted: 05/22/2014] [Indexed: 12/29/2022]
Abstract
Inducible systems for gene expression emerge as a new class of artificial vectors offering temporal and spatial exogenous control of gene expression. However, most inducible systems are less efficient in vivo and lack the target-organ specificity. In the present study, we have developed and optimized an oligonucleotide-based inducible system for the in vivo control of transgenes in the liver. We generated a set of simple, inducible plasmid-vectors based on the addition of four units of liver-specific miR-122 target sites to the 3′untranslated region of the gene of interest. Once the vector was delivered into hepatocytes this modification induced a dramatic reduction of gene expression that could be restored by the infusion of an antagomir for miR-122. The efficiency of the system was tested in vivo, and displayed low background and strong increase in gene expression upon induction. Moreover, gene expression was repeatedly induced even several months after the first induction showing no toxic effect in vivo. By combining tissue-specific control elements with antagomir treatment we generated, optimized and validated a robust inducible system that could be used successfully for in vivo experimental models requiring tight and cyclic control of gene expression.
Collapse
Affiliation(s)
- Iulian I Oprea
- 1] Department of Laboratory Medicine, Clinical Research Center, Karolinska Institutet, Karolinska University Hospital Huddinge, Huddinge, Sweden [2] Department of Pharmaceutical Technology and Biopharmaceutics, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania [3] Department of Oncology and Pathology, Cancer Center Karolinska, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden
| | - Joana R Viola
- Department of Laboratory Medicine, Clinical Research Center, Karolinska Institutet, Karolinska University Hospital Huddinge, Huddinge, Sweden
| | - Pedro M D Moreno
- Department of Laboratory Medicine, Clinical Research Center, Karolinska Institutet, Karolinska University Hospital Huddinge, Huddinge, Sweden
| | - Oscar E Simonson
- Department of Laboratory Medicine, Clinical Research Center, Karolinska Institutet, Karolinska University Hospital Huddinge, Huddinge, Sweden
| | - Sergey Rodin
- Division of Matrix Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden
| | | | - Karl Tryggvason
- Division of Matrix Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden
| | - Karin E Lundin
- Department of Laboratory Medicine, Clinical Research Center, Karolinska Institutet, Karolinska University Hospital Huddinge, Huddinge, Sweden
| | - Leonard Girnita
- Department of Oncology and Pathology, Cancer Center Karolinska, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden
| | - Carl Inge Edvard Smith
- Department of Laboratory Medicine, Clinical Research Center, Karolinska Institutet, Karolinska University Hospital Huddinge, Huddinge, Sweden
| |
Collapse
|
11
|
Zaghloul EM, Viola JR, Zuber G, Smith CIE, Lundin KE. Formulation and Delivery of Splice-Correction Antisense Oligonucleotides by Amino Acid Modified Polyethylenimine. Mol Pharm 2011. [DOI: 10.1021/mp200024q] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
12
|
Ezzat K, Andaloussi SEL, Zaghloul EM, Lehto T, Lindberg S, Moreno PMD, Viola JR, Magdy T, Abdo R, Guterstam P, Sillard R, Hammond SM, Wood MJA, Arzumanov AA, Gait MJ, Smith CIE, Hällbrink M, Langel Ü. PepFect 14, a novel cell-penetrating peptide for oligonucleotide delivery in solution and as solid formulation. Nucleic Acids Res 2011; 39:5284-98. [PMID: 21345932 PMCID: PMC3130259 DOI: 10.1093/nar/gkr072] [Citation(s) in RCA: 163] [Impact Index Per Article: 12.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Numerous human genetic diseases are caused by mutations that give rise to aberrant alternative splicing. Recently, several of these debilitating disorders have been shown to be amenable for splice-correcting oligonucleotides (SCOs) that modify splicing patterns and restore the phenotype in experimental models. However, translational approaches are required to transform SCOs into usable drug products. In this study, we present a new cell-penetrating peptide, PepFect14 (PF14), which efficiently delivers SCOs to different cell models including HeLa pLuc705 and mdx mouse myotubes; a cell culture model of Duchenne's muscular dystrophy (DMD). Non-covalent PF14-SCO nanocomplexes induce splice-correction at rates higher than the commercially available lipid-based vector Lipofectamine 2000 (LF2000) and remain active in the presence of serum. Furthermore, we demonstrate the feasibility of incorporating this delivery system into solid formulations that could be suitable for several therapeutic applications. Solid dispersion technique is utilized and the formed solid formulations are as active as the freshly prepared nanocomplexes in solution even when stored at an elevated temperatures for several weeks. In contrast, LF2000 drastically loses activity after being subjected to same procedure. This shows that using PF14 is a very promising translational approach for the delivery of SCOs in different pharmaceutical forms.
Collapse
Affiliation(s)
- Kariem Ezzat
- Department of Neurochemistry, Stockholm University, SE-106 91 Stockholm, Sweden.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Lehto T, Simonson OE, Mäger I, Ezzat K, Sork H, Copolovici DM, Viola JR, Zaghloul EM, Lundin P, Moreno PMD, Mäe M, Oskolkov N, Suhorutšenko J, Smith CIE, Andaloussi SEL. A peptide-based vector for efficient gene transfer in vitro and in vivo. Mol Ther 2011; 19:1457-67. [PMID: 21343913 DOI: 10.1038/mt.2011.10] [Citation(s) in RCA: 80] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023] Open
Abstract
Finding suitable nonviral delivery vehicles for nucleic acid-based therapeutics is a landmark goal in gene therapy. Cell-penetrating peptides (CPPs) are one class of delivery vectors that has been exploited for this purpose. However, since CPPs use endocytosis to enter cells, a large fraction of peptides remain trapped in endosomes. We have previously reported that stearylation of amphipathic CPPs, such as transportan 10 (TP10), dramatically increases transfection of oligonucleotides in vitro partially by promoting endosomal escape. Therefore, we aimed to evaluate whether stearyl-TP10 could be used for the delivery of plasmids as well. Our results demonstrate that stearyl-TP10 forms stable nanoparticles with plasmids that efficiently enter different cell-types in a ubiquitous manner, including primary cells, resulting in significantly higher gene expression levels than when using stearyl-Arg9 or unmodified CPPs. In fact, the transfection efficacy of stearyl-TP10 almost reached the levels of Lipofectamine 2000 (LF2000), however, without any of the observed lipofection-associated toxicities. Most importantly, stearyl-TP10/plasmid nanoparticles are nonimmunogenic, mediate efficient gene delivery in vivo, when administrated intramuscularly (i.m.) or intradermally (i.d.) without any associated toxicity in mice.
Collapse
Affiliation(s)
- Taavi Lehto
- Laboratory of Molecular Biotechnology, Institute of Technology, University of Tartu, Tartu, Estonia.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Andaloussi SEL, Lehto T, Mäger I, Rosenthal-Aizman K, Oprea II, Simonson OE, Sork H, Ezzat K, Copolovici DM, Kurrikoff K, Viola JR, Zaghloul EM, Sillard R, Johansson HJ, Said Hassane F, Guterstam P, Suhorutšenko J, Moreno PMD, Oskolkov N, Hälldin J, Tedebark U, Metspalu A, Lebleu B, Lehtiö J, Smith CIE, Langel U. Design of a peptide-based vector, PepFect6, for efficient delivery of siRNA in cell culture and systemically in vivo. Nucleic Acids Res 2011; 39:3972-87. [PMID: 21245043 PMCID: PMC3089457 DOI: 10.1093/nar/gkq1299] [Citation(s) in RCA: 215] [Impact Index Per Article: 16.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
While small interfering RNAs (siRNAs) have been rapidly appreciated to silence genes, efficient and non-toxic vectors for primary cells and for systemic in vivo delivery are lacking. Several siRNA-delivery vehicles, including cell-penetrating peptides (CPPs), have been developed but their utility is often restricted by entrapment following endocytosis. Hence, developing CPPs that promote endosomal escape is a prerequisite for successful siRNA implementation. We here present a novel CPP, PepFect 6 (PF6), comprising the previously reported stearyl-TP10 peptide, having pH titratable trifluoromethylquinoline moieties covalently incorporated to facilitate endosomal release. Stable PF6/siRNA nanoparticles enter entire cell populations and rapidly promote endosomal escape, resulting in robust RNAi responses in various cell types (including primary cells), with minimal associated transcriptomic or proteomic changes. Furthermore, PF6-mediated delivery is independent of cell confluence and, in most cases, not significantly hampered by serum proteins. Finally, these nanoparticles promote strong RNAi responses in different organs following systemic delivery in mice without any associated toxicity. Strikingly, similar knockdown in liver is achieved by PF6/siRNA nanoparticles and siRNA injected by hydrodynamic infusion, a golden standard technique for liver transfection. These results imply that the peptide, in addition to having utility for RNAi screens in vitro, displays therapeutic potential.
Collapse
|
15
|
Zaghloul EM, Viola JR, Zuber G, Smith CIE, Lundin KE. Formulation and delivery of splice-correction antisense oligonucleotides by amino acid modified polyethylenimine. Mol Pharm 2010; 7:652-63. [PMID: 20128628 DOI: 10.1021/mp900220p] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Splice-correcting phosphorothioate RNA antisense oligonucleotides with 2'-O-methyl modifications (ASO) are promising therapeutic agents for several disorders caused by aberrant splicing. However, their usefulness is hindered by the lack of efficient delivery. Unmodified 25 kDa polyethylenimine (PEI) has shown potential for plasmid delivery but seems to be less efficient for short nucleic acid sequences. Herein, we have evaluated several amino acid modified PEI molecules as carriers for ASO. By characterization of their properties, such as size, stability and transfection into mammalian cells, we have identified tyrosine-modified PEI (PEIY) as an efficient ASO delivery system. HeLa705 cells containing an aberrant luciferase gene, interrupted by a mutated beta-globin intron, were used to assess the splice correction effectiveness mediated by the various modified PEI/ASO polyplexes. PEIY has a self-assembly nature, as opposed to the highly cationic parent polymer, which is relevant for the stability of the PEIY/ASO complexes. As a result, at an optimal ratio of 20:1 (+/-), the complexes that formed significantly corrected the splicing on both the mRNA and the protein levels. ASO formulated with PEIY enhanced luciferase activity up to 450-fold. This increase was three times higher than that produced by the commercially available transfection agent Lipofectamine. PEIY/ASO polyplexes resulted in at least 80% correct splicing of the transcript. Moreover, extremely low doses of ASO (0.025 microM) showed significant splice correction represented by 150-fold increase of luciferase activity and 47% mRNA correction. Our findings suggest key parameters for formulating active complexes and reveal a new platform that can be further developed for ASO in vivo targeting.
Collapse
Affiliation(s)
- Eman M Zaghloul
- Department of Laboratory Medicine, Karolinska Institute, Sweden.
| | | | | | | | | |
Collapse
|
16
|
Viola JR, El-Andaloussi S, Oprea II, Smith CIE. Non-viral nanovectors for gene delivery: factors that govern successful therapeutics. Expert Opin Drug Deliv 2010; 7:721-35. [DOI: 10.1517/17425241003716810] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
|
17
|
Lehto T, Abes R, Oskolkov N, Suhorutsenko J, Copolovici DM, Mäger I, Viola JR, Simonson OE, Ezzat K, Guterstam P, Eriste E, Smith CIE, Lebleu B, Samir El Andaloussi, Langel U. Delivery of nucleic acids with a stearylated (RxR)4 peptide using a non-covalent co-incubation strategy. J Control Release 2009; 141:42-51. [PMID: 19744531 DOI: 10.1016/j.jconrel.2009.08.028] [Citation(s) in RCA: 101] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2009] [Revised: 08/21/2009] [Accepted: 08/28/2009] [Indexed: 11/29/2022]
Abstract
In recent years, oligonucleotide-based molecules have been intensely used to modulate gene expression. All these molecules share the common feature of being essentially impermeable over cellular membranes and they therefore require efficient delivery vectors. Cell-penetrating peptides are a group of delivery peptides that has been readily used for nucleic acid delivery. In particular, polyarginine and derivates thereof, i.e. the (RxR)(4) peptide, have been applied with success both in vitro and in vivo. A major problem, however, with these arginine-rich peptides is that they frequently remain trapped in endosomal compartments following internalization. The activity of polyarginine has previously been improved by conjugation to a stearyl moiety. Therefore, we sought to investigate what impact such modification would have on the pre-clinically used (RxR)(4) peptide for non-covalent delivery of plasmids and splice-correcting oligonucleotides (SCOs) and compare it with stearylated Arg9 and Lipofectamine 2000. We show that stearyl-(RxR)(4) mediates efficient plasmid transfections in several cell lines and the expression levels are significantly higher than when using unmodified (RxR)(4) or stearylated Arg9. Although the transfection efficiency is lower than with Lipofectamine 2000, we show that stearyl-(RxR)(4) is substantially less toxic. Furthermore, using a functional splice-correction assay, we show that stearyl-(RxR)(4) complexed with 2'-OMe SCOs promotes significant splice correction whereas stearyl-Arg9 fails to do so. Moreover, stearyl-(RxR)(4) promotes dose-dependent splice correction in parity with (RxR)(4)-PMO covalent conjugates, but at least 10-times lower concentration. These features make this stearic acid modified analog of (RxR)(4) an intriguing vector for future in vivo experiments.
Collapse
Affiliation(s)
- Taavi Lehto
- Laboratory of Molecular Biotechnology, Institute of Technology, University of Tartu, Nooruse 1, 50411 Tartu, Estonia.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|